CTRI/2023/08/057070尚未招募Unknown
A Multicenter, Observational, Postmarketing Study to Evaluate the Safety of AmBisome® in Clinical Practice in India - NI
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1) Male or female patient older than 1 month (inclusive) at the time AmBisome treatment was started
- •2) Patients who have commenced treatment with AmBisome in accordance with the local routine clinical practice at any time between 01 June 2021 and 30 September 2022 (inclusive)
排除标准
- •1) Patients treated by AmBisome in the framework of a clinical study
- •2) Patients who initiated treatment with other amphotericin B products, including liposomal amphotericin B products
- •3) Patients who initiated AmBisome treatment but switched to other amphotericin B products, including other liposomal amphotericin B products, due to non-clinical reasons (e.g. supply issues)
研究者
相似试验
进行中（未招募）
4 期
Study to evaluate safety and performance of the Evermine 50- 50µm Everolimus Eluting Coronary Stent System (EES) in the treatment of patients with de novo coronary artery lesionsCTRI/2017/02/007781Meril Life Sciences Pvt Ltd118
尚未招募
4 期
Prospective, multicenter, post-marketing study to evaluate the effectiveness of a monofocal implantable phakic contact lens (IPCL) in myopic and hyperopic patients, with and without astigmatismH52Disorders of refraction and accommodationDRKS00024073Care Group, India40
进行中（未招募）
1 期
Study of Voncento® in Subjects with Von Willebrand DiseaseVon Willebrand DiseaseMedDRA version: 18.1Level: PTClassification code 10047715Term: Von Willebrand's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-003305-25-IECSL Behring GmbH30
进行中（未招募）
1 期
An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects with Von Willebrand DiseaseEUCTR2013-003305-25-ATCSL Behring GmbH20
进行中（未招募）
1 期
Study of Voncento® in Subjects with Von Willebrand DiseaseEUCTR2013-003305-25-GRCSL Behring GmbH26